VKTX up 28% on Q2 report out

What drove stock move?

⇨ VK2735 oral 💊
» Oral dosing up to 80 mg looks tolerable enough to go to 100 mg
» No more catalyst drought with Obesity Week oral VK2735 readout added in Q4 (see 📸 for updated 2024 readouts)
» Should be an exciting Obesity Week 2024

⇨ VK2735 subq 💉
» Can go right to Ph3 based on FDA feedback - no Ph2b needed
» Testing monthly subq VK2735 based on PK data

⇨ VK2809 in NASH
» Still looking to partner Ph3/MACE

⇨ VK0214 X-ALD
» Still reading out in Q4

⇨ Dual amylin and calcitonin receptor agonist in obesity
» moving into clinic in 2025

⇨ Re partnerships (M&A?) 🤝
» VKTX CEO: “We've been consistent with our receptivity to interests and opportunities and we remain so.”

⇨ Ended quarter with lots of cash - $942M 💰